机构:[1]Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.[2]Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.[3]Shanghai Majorbio Bio-Pharm Technology Co., Ltd., Shanghai, China.[4]Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.[5]School of Chemical Engineering, Sichuan University of Science and Engineering, Zigong, Sichuan, China.
National Nature Science Foundation
of China (Nos 82374085, 82373317, 22377087, and 82303818);
the Natural Science Foundation of Shanghai (Nos 23ZR1460500
and 21ZR1464400).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类|2 区医学
小类|2 区药学
最新[2023]版:
大类|2 区医学
小类|2 区药学
第一作者:
第一作者机构:[1]Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
通讯作者:
推荐引用方式(GB/T 7714):
Fang Qiao-Yu,Wang Yue-Ping,Zhang Rui-Qin,et al.Carnosol ameliorated cancer cachexia-associated myotube atrophy by targeting P5CS and its downstream pathways[J].Frontiers In Pharmacology.2023,14:1291194.doi:10.3389/fphar.2023.1291194.
APA:
Fang Qiao-Yu,Wang Yue-Ping,Zhang Rui-Qin,Fan Meng,Feng Li-Xing...&Liu Xuan.(2023).Carnosol ameliorated cancer cachexia-associated myotube atrophy by targeting P5CS and its downstream pathways.Frontiers In Pharmacology,14,
MLA:
Fang Qiao-Yu,et al."Carnosol ameliorated cancer cachexia-associated myotube atrophy by targeting P5CS and its downstream pathways".Frontiers In Pharmacology 14.(2023):1291194